We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Read MoreHide Full Article
Key Takeaways
ZBH posted Q4 adjusted EPS of $2.42, beating estimates by 1.7%, as revenues rose 10.9% to $2.24B.
ZBH saw U.S. and international sales climb double digits, with all four product categories growing.
ZBH shares rose 1.4% pre-market as guidance called for 2.5-4.5% revenue growth despite margin pressure.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42, which beat the Zacks Consensus Estimate by 1.7%. The adjusted figure rose 4.8% year over year.
The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives, inventory and manufacturing-related charges and European Union Medical Device Regulation-related charges, among others.
GAAP EPS was 70 cents compared with $1.20 in the year-ago period.
Full-year adjusted EPS was $8.20, marking an increase of 2.5% year over year. The figure marginally beat the Zacks Consensus Estimate by 0.5%.
ZBH's Revenues
Net sales of $2.24 billion increased 10.9% (up 9.2% on a constant currency basis) year over year. The figure surpassed the Zacks Consensus Estimate by 1.9%.
However, following the announcement, shares of ZBH rose 1.4% in pre-market trading today.
Full-year net sales of $8.23 billion increased 7.2% (up 6.4% on a constant currency basis). The figure marginally topped the Zacks Consensus Estimate by 0.5%.
ZBH's Revenues by Geography
Sales generated in the United States totaled $1.31 billion (up 11.11% year over year) for the quarter, while International sales grossed $931.2 million (up 10.6% year over year on a reported basis and 6.6% at CER).
Segmental Analysis of ZBH's Revenues
The company currently reports under four product categories — Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) and Technology & Data, Bone Cement and Surgical.
Sales in the Knees unit improved 8.6% year over year at CER to $911 million.
Hips sales grew 6.8% year over year at CER to $555.4 million.
Revenues in the S.E.T. unit rose 20.1% year over year at CER to $587.6 million.
Technology & Data, Bone Cement and Surgical (historically referred to as "Other") revenues rose 8.7% to $189.8 million at CER in the fourth quarter.
ZBH's Margin Performance
Adjusted gross margin, after excluding the impact of intangible asset amortization, was 64.7%, reflecting a contraction of 632 basis points (bps) year over year. Gross margin contracted due to a 35.1% rise in the cost of products sold.
Selling, general and administrative expenses rose 16.8% to $872.3 million. Research and development expenses rose 9.6% to $118.8 million. Adjusted operating margin contracted 821 bps to 20.5%.
ZBH's Cash Position
Zimmer Biomet exited the fourth quarter with cash and cash equivalents of $591.9 million compared with $525.5 million at the end of the fourth quarter of 2024.
Cumulative net cash provided by operating activities at the end of the fourth quarter was $1.70 billion compared with $1.50 billion in the year-ago period.
Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise
Revenue growth is expected to be in the band of 2.5-4.5%. The Zacks Consensus Estimate for revenues is pegged at $8.41 billion, implying 3.1% year-over-year growth.
Adjusted EPS guidance for the full year is expected to be in the range of $8.30-$8.45. The Zacks Consensus Estimate for 2025 adjusted EPS is pegged at $8.54.
Our Take on ZBH
Zimmer Biomet exited the fourth quarter with better-than-expected results, wherein both earnings and revenues beat estimates. All the business segments reported growth in the quarter.
Notable developments that fueled growth includes FDA clearance for ROSA Knee with OptimiZe and the launch of Brachiator Mini-Rail External Fixation System through its Paragon 28 subsidiary.
On the flip side, the contraction of both the margins looks discouraging.
ZBH's Zacks Rank and Key Picks
Zimmer Biomet currently has a Zacks Rank #3 (Hold).
Envista, carrying a Zacks Rank #1 (Strong Buy) at present, posted fourth-quarter 2025 adjusted EPS of 38 cents, which exceeded the Zacks Consensus Estimate by 18.2%. Revenues of $750.6 million surpassed the Zacks Consensus Estimate by 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NVST has an earnings yield of 3.7% compared with the industry’s 2.3% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 16.4%.
National Vision, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2025 adjusted EPS of 13 cents, which topped the Zacks Consensus Estimate by 8.3%. Revenues of $487.3 million beat the Zacks Consensus Estimate by 2.7%.
EYE’s earnings yield of 5.8% compares favorably with the industry’s 2.8% yield. The company beat on earnings in each of the trailing four quarters, the average surprise being 2.75%.
Resmed, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 EPS of $2.81, which beat the Zacks Consensus Estimate by 46%. Revenues of $1.42 billion topped the Zacks Consensus Estimate by 2.3%.
RMD has an earnings yield of 7.1% compared with the industry’s 2.8% yield. The company’s earnings outperformed estimates in three of the trailing four quarters and missed in the other one, with the average surprise being 2.7%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Key Takeaways
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42, which beat the Zacks Consensus Estimate by 1.7%. The adjusted figure rose 4.8% year over year.
The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives, inventory and manufacturing-related charges and European Union Medical Device Regulation-related charges, among others.
GAAP EPS was 70 cents compared with $1.20 in the year-ago period.
Full-year adjusted EPS was $8.20, marking an increase of 2.5% year over year. The figure marginally beat the Zacks Consensus Estimate by 0.5%.
ZBH's Revenues
Net sales of $2.24 billion increased 10.9% (up 9.2% on a constant currency basis) year over year. The figure surpassed the Zacks Consensus Estimate by 1.9%.
However, following the announcement, shares of ZBH rose 1.4% in pre-market trading today.
Full-year net sales of $8.23 billion increased 7.2% (up 6.4% on a constant currency basis). The figure marginally topped the Zacks Consensus Estimate by 0.5%.
ZBH's Revenues by Geography
Sales generated in the United States totaled $1.31 billion (up 11.11% year over year) for the quarter, while International sales grossed $931.2 million (up 10.6% year over year on a reported basis and 6.6% at CER).
Segmental Analysis of ZBH's Revenues
The company currently reports under four product categories — Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) and Technology & Data, Bone Cement and Surgical.
Sales in the Knees unit improved 8.6% year over year at CER to $911 million.
Hips sales grew 6.8% year over year at CER to $555.4 million.
Revenues in the S.E.T. unit rose 20.1% year over year at CER to $587.6 million.
Technology & Data, Bone Cement and Surgical (historically referred to as "Other") revenues rose 8.7% to $189.8 million at CER in the fourth quarter.
ZBH's Margin Performance
Adjusted gross margin, after excluding the impact of intangible asset amortization, was 64.7%, reflecting a contraction of 632 basis points (bps) year over year. Gross margin contracted due to a 35.1% rise in the cost of products sold.
Selling, general and administrative expenses rose 16.8% to $872.3 million. Research and development expenses rose 9.6% to $118.8 million. Adjusted operating margin contracted 821 bps to 20.5%.
ZBH's Cash Position
Zimmer Biomet exited the fourth quarter with cash and cash equivalents of $591.9 million compared with $525.5 million at the end of the fourth quarter of 2024.
Cumulative net cash provided by operating activities at the end of the fourth quarter was $1.70 billion compared with $1.50 billion in the year-ago period.
Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise
Zimmer Biomet Holdings, Inc. price-consensus-eps-surprise-chart | Zimmer Biomet Holdings, Inc. Quote
ZBH’s 2026 Outlook
Zimmer Biomet has provided its guidance for 2026.
Revenue growth is expected to be in the band of 2.5-4.5%. The Zacks Consensus Estimate for revenues is pegged at $8.41 billion, implying 3.1% year-over-year growth.
Adjusted EPS guidance for the full year is expected to be in the range of $8.30-$8.45. The Zacks Consensus Estimate for 2025 adjusted EPS is pegged at $8.54.
Our Take on ZBH
Zimmer Biomet exited the fourth quarter with better-than-expected results, wherein both earnings and revenues beat estimates. All the business segments reported growth in the quarter.
Notable developments that fueled growth includes FDA clearance for ROSA Knee with OptimiZe and the launch of Brachiator Mini-Rail External Fixation System through its Paragon 28 subsidiary.
On the flip side, the contraction of both the margins looks discouraging.
ZBH's Zacks Rank and Key Picks
Zimmer Biomet currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Envista (NVST - Free Report) , National Vision (EYE - Free Report) and Resmed (RMD - Free Report) .
Envista, carrying a Zacks Rank #1 (Strong Buy) at present, posted fourth-quarter 2025 adjusted EPS of 38 cents, which exceeded the Zacks Consensus Estimate by 18.2%. Revenues of $750.6 million surpassed the Zacks Consensus Estimate by 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NVST has an earnings yield of 3.7% compared with the industry’s 2.3% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 16.4%.
National Vision, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2025 adjusted EPS of 13 cents, which topped the Zacks Consensus Estimate by 8.3%. Revenues of $487.3 million beat the Zacks Consensus Estimate by 2.7%.
EYE’s earnings yield of 5.8% compares favorably with the industry’s 2.8% yield. The company beat on earnings in each of the trailing four quarters, the average surprise being 2.75%.
Resmed, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 EPS of $2.81, which beat the Zacks Consensus Estimate by 46%. Revenues of $1.42 billion topped the Zacks Consensus Estimate by 2.3%.
RMD has an earnings yield of 7.1% compared with the industry’s 2.8% yield. The company’s earnings outperformed estimates in three of the trailing four quarters and missed in the other one, with the average surprise being 2.7%.